摘要
目的:探讨低分子肝素治疗子痫前期合并胎儿生长受限的疗效。方法:将60例子痫前期患者分为3组:子痫前期合并FGR肝素治疗组、子痫前期合并FGR传统治疗组和子痫前期不合并FGR组,每组各20例;选取同期正常住院待产孕妇20例作为对照组。监测胎儿生长情况、生物物理评分,同时监测血小板计数(PLT)、凝血酶原时间(PT)、部分凝血活酶时间(APTT);并记录羊水、胎龄、新生儿体重和新生儿1分钟Apgar评分。结果:低分子肝素治疗子痫前期合并FGR组,与传统治疗组比较,肝素治疗组:胎儿生长情况明显改善,生物物理评分及羊水指数明显提高,胎龄显著延长、新生儿体重显著增加,新生儿1分钟Apgar评分显著提高,P<0.05。低分子肝素治疗前后PLT、PT、APTT比较,差异无显著性,P>0.05。结论:低分子肝素能促进胎儿生长发育,治疗子痫前期合并FGR是较为安全的。
Objective： To explore the effect of low molecular heparin on preeclampsia and fetal growth restriction （FGR）. Methods： 60 preeclampsia women were divided into 3 groups： preeclampsia and FGR treated with heparin （heparin group, 20 cases）,preeclampsia and FGR treated with traditional drugs （traditional treatment group, 20 cases）, preeclampsia group （20 cases）, 20 healthy pregnant women were selected as control group. Fetal growth situation, biophysics value, platelet count （ PLT ）, prothrombin time （PT）, activated partial thromboplastin time （APTT） were detected, index of amniotic fluid, gestational age, weight of neonates and Apgar value for 1 minute were recorded. Results ： Fetal growth situation, biophysics value, index of amniotic fluid, gestational age and Apgar value for 1 minute in heparin group were significantly higher than those in traditional treatment group, and weight of neonates in heparin group was heavier than that in traditional treatment group （ P 〈 0. 05 ） ; but there was no difference in PLT, PT and APTT between before and after hep- arin treatment （ P 〉 0. 05 ） . Conclusion ： Low molecular heparin can promote the growth and development of neonates, which is a safe drug for patients with preeclampsia and fetal growth restriction.
出处
《中国妇幼保健》
CAS
北大核心
2009年第7期917-919,共3页
Maternal and Child Health Care of China
基金
2007年佛山市科技局科研立项课题(项目编号:200708088)
关键词
低分子肝素
子痫前期
胎儿生长受限
疗效
Low molecular heparin
Preeclampsia
Fetal growth restriction
Effect
